Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, Abeona Therapeutics Inc (NASDAQ: ABEO) closed at $4.99 down -5.49% from its previous closing price of $5.28. In other words, the price has decreased by -$5.49 from its previous closing price. On the day, 2.63 million shares were traded. ABEO stock price reached its highest trading level at $5.26 during the session, while it also had its lowest trading level at $4.97.
Ratios:
For a deeper understanding of Abeona Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.65 and its Current Ratio is at 6.73. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.11.
On March 05, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $16.
On July 03, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $15.H.C. Wainwright initiated its Buy rating on July 03, 2024, with a $15 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 16 ’25 when Seshadri Vishwas sold 249 shares for $5.49 per share. The transaction valued at 1,366 led to the insider holds 1,189,818 shares of the business.
Seshadri Vishwas bought 249 shares of ABEO for $1,366 on Oct 16 ’25. On Sep 29 ’25, another insider, O’Malley Brendan M., who serves as the SVP, Chief Legal Officer of the company, sold 9,366 shares for $5.39 each. As a result, the insider received 50,516 and left with 350,763 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABEO now has a Market Capitalization of 255879904 and an Enterprise Value of 54437908. As of this moment, Abeona’s Price-to-Earnings (P/E) ratio for their current fiscal year is 7.91. For the stock, the TTM Price-to-Sale (P/S) ratio is 639.70 while its Price-to-Book (P/B) ratio in mrq is 1.56. Its current Enterprise Value per Revenue stands at 136.095 whereas that against EBITDA is -0.752.
Stock Price History:
The Beta on a monthly basis for ABEO is 1.45, which has changed by -0.22152889 over the last 52 weeks, in comparison to a change of 0.20772064 over the same period for the S&P500. Over the past 52 weeks, ABEO has reached a high of $7.54, while it has fallen to a 52-week low of $3.93. The 50-Day Moving Average of the stock is -15.78%, while the 200-Day Moving Average is calculated to be -13.77%.
Shares Statistics:
For the past three months, ABEO has traded an average of 881.77K shares per day and 1180640 over the past ten days. A total of 51.25M shares are outstanding, with a floating share count of 45.68M. Insiders hold about 10.91% of the company’s shares, while institutions hold 66.04% stake in the company. Shares short for ABEO as of 1760486400 were 9188242 with a Short Ratio of 10.42, compared to 1757894400 on 8733509. Therefore, it implies a Short% of Shares Outstanding of 9188242 and a Short% of Float of 19.18.
Earnings Estimates
At present, 4.0 analysts are actively evaluating the performance of Abeona Therapeutics Inc (ABEO) in the stock market.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.05 and low estimates of -$0.27.
Analysts are recommending an EPS of between $1.15 and -$1.45 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.08, with 4.0 analysts recommending between $0.15 and -$0.47.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $21.65M. There is a high estimate of $27.18M for the next quarter, whereas the lowest estimate is $12M.
Based on 7 analysts’ estimates, the company’s revenue will be $116.68M in the next fiscal year. The high estimate is $140.3M and the low estimate is $96.1M.
